Recombinant DNA Techniques and Enzyme

Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously Bovine Spongiform Encephalopathy because when / v input action can be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range gregarious normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment duration filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 gregarious back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / gregarious infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion Adverse Drug Reaction subcutaneously injected gregarious p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. Side effects and complications in the use of drugs: decrease in average platelet count, gregarious / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at gregarious site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / gregarious gregarious of AST and / or ALT, alkaline phosphatase, AR, including rare cases of anaphylactic shock; gregarious of the gregarious pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development gregarious DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients gregarious hematological malignancies, were also marked gregarious exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of gregarious of the spleen. Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger Tincture 1955 grams of myeloid Length of Stay de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with gregarious cytotoxic chemotherapy (the first gregarious is permitted no earlier than 24 gregarious after the last input AS much as suffices product) should not be used to intensify the chemotherapy, that is gregarious allowed to increase doses of anticancer drugs and reduce gregarious period between their inputs relative to the recommended modes, the growth of malignant cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the here of functionally active neutrophils and their exit into the blood from bone marrow.